title: [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
abstract: OBJECTIVE
  To explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  The efficacy and side effects of icotinib hydrochloride in treatment of 59 cases with stage IV NSCIC and followed-up from March 2009 to January 2012 were retrospectively analyzed.
  
  
  RESULTS
  Twenty seven patients (45.8%) showed partial response (PR), 17 patients (28.8%) achieved SD, and 15 (25.4%) had progressive disease. The objective response rate (ORR) was 45.8% (27/59), and disease control rate (DCR) was 74.6% (44/59). Among the 23 patients with EGFR mutation, ORR was 73.9% (17/23), and DCR was 95.7% (22/23). Thirty six patients (61.0%) achieved remission of symptoms to varying degrees. The main symptoms relieved were cough, asthmatic suffocating, pain and hoarseness. The major adverse events were mild skin rash (35.6%) and diarrhea (15.3%). Others were dry skin, nausea and stomach problems. The efficacy of icotinib hydrochloride were related to the ECOG performance status, smoking history, EGFR mutation and rash significantly (P < 0.05).
  
  
  CONCLUSIONS
  Monotherapy with icotinib hydrochloride is effective and tolerable for patients with advanced NSCLC, especially with EGFR mutation.
authors.affiliation: Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Xin-jie
authors.initials: XJ
authors.lastname: Yang
authors.forename: Yi-fen
authors.initials: YF
authors.lastname: Sun
authors.forename: Na
authors.initials: N
authors.lastname: Qin
authors.forename: Jia-lin
authors.initials: JL
authors.lastname: Lü
authors.forename: Yu-hua
authors.initials: YH
authors.lastname: Wu
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.forename: Shu-cai
authors.initials: SC
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D043844:Crown Ethers / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics*; D005076:Exanthema / Q000139:chemically induced; D005091:Exons; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib; D066246:ErbB Receptors